Supplemental Oxygen Decreases Cardiac Effort in Pulmonary Arterial Hypertension

Methamphetamine-associated pulmonary arterial hypertension (Meth-PAH) is an increasingly prevalent but understudied subtype of Group 1 pulmonary arterial hypertension (PAH).

In patients with pulmonary arterial hypertension (PAH), limited real-world data are available on persistence to oral treprostinil therapy, particularly while transitioning from parenteral prostacyclins. 

An on-demand recording of PVRI’s December PH Community Call, featuring informal discussion on emerging science and patient-focused research in pulmonary hypertension. The session covers new insights into hypoxic PH mechanisms and exercise interventions in PAH, with expert-led moderation and open exchange.

Pulmonary arterial hypertension (PAH) is a progressive disease with significant morbidity and mortality. Due to nonspecific symptoms, diagnosis can be challenging and subject to substantial delays. Using data from Mayo Clinic′s electronic health records, we looked at causes of delayed diagnosis and whether earlier diagnosis means better outcomes.